Gri Bio, Inc. (GRI) Stock Price & Analysis

Gri Bio, Inc. (GRI) rose 0.00% to USD 1.45 as of July 25, 2026 at 04:27 UTC, according to Nexqual real-time market data.

GRI last closed at USD 1.45; the session ranged USD 1.42–1.52 on volume of 29,758 shares. Market capitalization is —, with a 52-week range of USD 1.41–80.36 (NCM). Source: Nexqual, July 25, 2026 at 04:27 UTC.

Key Statistics (as of July 25, 2026 at 04:27 UTC)

Technical Analysis (GRI)

Nexqual's technical model rates GRI "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:27 UTC.

From Gri Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-01-30)

Key Strengths & Strategy (as disclosed to the SEC)

• It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. • If we do not obtain patent term extension and data exclusivity or similar protections to extend the term of patent protection covering any product candidates which we may develop, our business may be materially harmed.
• NKT Cells and the Immune System Our approach is founded on the discovery that NKT cells are a functional link between the innate and adaptive immune systems and that dysregulated immune responses can be reset by regulating the activity of NKT cells to potentially treat a broad array of acute and chronic conditions. __________________ Figure 2.

Partnerships

• Food and Drug Administration (FDA) approval of any of our product candidates, if any, we may never obtain approval or commercialize these product candidates outside of the United States, which could limit our ability to realize their full market potential. • We may enter, or attempt to enter, into collaborations with third parties for the development and commercialization of our product candidates, and these collaboration would be important to our business.
• Based on the results of the Phase 2a trial, and subject to obtaining the requisite additional funding or resources, we plan to initiate (either ourselves or in partnership with a strategic partner) a Phase 2b trial that could support an application for conditional approval of GRI-0621 in the European Union and could have the potential to be regarded as a registrational trial in the United States. • Advance GRI-0803 through Phase 1a/1b studies initially targeting SLE .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:27 UTC. This page is informational and not investment advice.